Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB 100 million in a Series A financing round. Tsing Song Capital led the investment round, with additional investments from Wuhe Capital, Aeonmed, and Pinnacles Medtech.
Established in 2021, Genewise Bio has developed a comprehensive independent research and development and manufacturing system. It integrates microfluidic chips, diagnostic reagents, and testing equipment to create innovative point-of-care testing (POCT) molecular diagnostic platforms. The company focuses on pathogen detection, drug resistance gene detection, and maternal and child health. Genewise Bio has received over 20 Category III device approvals from the National Medical Products Administration (NMPA) and CE marks for its products.- Flcube.com
